Global Pulmonary Edema Therapeutics Market: Overview
Pulmonary edema is a medical condition caused by the accumulation of excess fluid in the air sacs of lungs. Accumulation of fluids in the lungs occurs primarily due to underlying medical conditions such as congestive heart failure. The causes of pulmonary edema include pneumonia, injury to chest wall, exposure to toxic gases or certain medications, and exercising at high elevations. The pulmonary edema creates several breathing problems and if left untreated could lead to failure of the respiratory system. The common symptoms of pulmonary edema include difficulty in breathing, feeling of suffocation, anxiety, restlessness, and rapid, irregular heartbeats. The pulmonary edema can be either acute, which occurs with sudden onset, or chronic that occurs over a period of time.
Global Pulmonary Edema Therapeutics Market: Key Trends
The global pulmonary edema therapeutics market is primarily driven by high prevalence and increase in incidence rate of congestive heart disorder across the globe. For instance, an estimated 26 million people are affected by congestive heart failure and the incidence rate is rising significantly across the world. Increase in the number of road traffic accidents leading to severe injury to chest, changing lifestyles, and rapidly rising toxic air pollution in industrialized countries are also projected to fuel the growth of the global pulmonary edema therapeutics market during the forecast period. Moreover, new product launches and large number of therapeutic drug candidates under clinical trial studies are anticipated to boost the growth of the market.
Global Pulmonary Edema Therapeutics Market: Segmentation
The global pulmonary edema therapeutics market can be categorized based on type of pulmonary edema, cause of pulmonary edema, treatment, distribution channel, and region. In terms of type of pulmonary edema, the global market can be bifurcated into acute pulmonary edema and chronic pulmonary edema. The chronic pulmonary edema segment is expected to account for major share of the global market by 2027. Based on cause of pulmonary edema, the global pulmonary edema therapeutics market can be classified into cardiogenic pulmonary edema and non-cardiogenic pulmonary edema. Cardiogenic pulmonary edema is caused by increased pressure in the left ventricle to pump out required amount of blood to the lungs. Non-cardiogenic edema is caused by the accumulation of fluids in the lungs due to leakage of the blood capillaries in the lungs. The treatment of pulmonary edema includes diuretic treatment, morphine treatment, where narcotics are used to relive the symptoms of short breath, and blood pressure medications. In terms of distribution channel, the global market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
Global Pulmonary Edema Therapeutics Market: Regional Analysis
In terms of region, the global pulmonary edema therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are anticipated to account for major shares of the global market, due to a large population afflicted with pulmonary edema and congestive heart disorders. Moreover, easy availability of therapeutic drugs, increase in awareness about the disease indication, high per capita health care expenditure, and significantly large geriatric population augment the market in these region. The pulmonary edema therapeutics market in Asia Pacific is expected to expand at a high CAGR during the forecast period due to rise in prevalence of pulmonary edema in highly populous countries such as India and China, rapidly changing health care systems and government initiatives to improve overall health care Moreover, rise in investments by leading global pharmaceutical companies and large base of pharmaceutical companies are likely to contribute to the growth of the market in Asia Pacific in the near future.
Global Pulmonary Edema Therapeutics Market: Competitive Landscape
Key players operating in the global pulmonary edema therapeutics market include Clarus Therapeutics, Inc., Pfizer, Inc., Novartis AG, Gilead Sciences, Inc. Merck & Co., Inc., Sage Therapeutics, Jazz Pharmaceuticals plc, Amneal Pharmaceutical LLC, and Par Pharmaceutical, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.